Skip to content

Intra-Cellular Therapies, Inc.: 10-Q filed 2014-08-12

What Intra-Cellular Therapies, Inc. reported in its quarterly report filed 2014-08-12 (fiscal Q2 2014): 29 published measures, 75 facts as tagged in accession 0001193125-14-306672.

This filing

Form
10-Q (quarterly report)
Filed
2014-08-12
Fiscal period
fiscal Q2 2014
Accession
0001193125-14-306672 on SEC EDGAR

Values are as tagged in this filing. A later filing can restate them; each measure links to its history page, which shows the latest-filed value per period. All Intra-Cellular Therapies, Inc. filings.

Reported measures

Total assets

Resources recognized on the balance sheet. Book assets are not the market value of the business.

PeriodValueUnitDays
At 2014-06-30141,342,810USD
At 2013-12-3138,449,312USD

Stockholders equity

The reported residual interest after liabilities. It is an accounting amount, not market capitalization.

PeriodValueUnitDays
At 2014-06-30138,603,556USD
At 2013-12-3131,615,275USD

Cash and cash equivalents

Cash and qualifying short-term liquid investments under the filer’s accounting policy. Restricted cash and longer-term investments may be reported separately.

PeriodValueUnitDays
At 2014-06-3091,140,138USD
At 2013-12-3135,150,924USD
At 2013-06-308,340,347USD
At 2012-12-3115,645,528USD

Net income or loss

Reported profit or loss for the period. Check the filing for attribution, exceptional items and discontinued operations before comparing companies.

PeriodValueUnitDays
2014-04-01 to 2014-06-30-4,533,539USD91
2014-01-01 to 2014-06-30-9,076,823USD181
2013-04-01 to 2013-06-30-8,277,391USD91
2013-01-01 to 2013-06-30-13,915,768USD181

Capital expenditure payments

Cash payments to acquire property, plant and equipment. This taxonomy concept does not capture every form of investment or acquisition.

PeriodValueUnitDays
2014-01-01 to 2014-06-308,325USD181
2013-01-01 to 2013-06-308,843USD181

Revenue

Revenue under this specific accounting concept. A missing value is not zero; filers can use other revenue concepts.

PeriodValueUnitDays
2014-04-01 to 2014-06-30219,238USD91
2014-01-01 to 2014-06-30387,025USD181
2013-04-01 to 2013-06-30643,264USD91
2013-01-01 to 2013-06-301,241,516USD181

Retained earnings or deficit

Accumulated undistributed earnings or deficit at the reporting date. This balance is not cash available for distribution.

PeriodValueUnitDays
At 2014-06-30-66,641,320USD
At 2013-12-31-57,564,497USD

Net property, plant and equipment

Carrying amount of property, plant and equipment after accumulated depreciation, depletion and amortization. It is not replacement cost or market value.

PeriodValueUnitDays
At 2014-06-3063,850USD
At 2013-12-3168,272USD

Share-based compensation expense

Reported noncash expense for share-based payment arrangements. Noncash treatment does not mean the awards have no economic cost to shareholders.

PeriodValueUnitDays
2014-04-01 to 2014-06-30290,461USD91
2014-01-01 to 2014-06-30490,215USD181
2013-04-01 to 2013-06-3089,163USD91
2013-01-01 to 2013-06-30163,233USD181

Operating income or loss

Operating revenue less operating expenses for the reporting period. It excludes items outside the reported operating result and is not free cash flow.

PeriodValueUnitDays
2014-04-01 to 2014-06-30-4,611,584USD91
2014-01-01 to 2014-06-30-9,186,047USD181
2013-04-01 to 2013-06-30-8,048,043USD91
2013-01-01 to 2013-06-30-13,448,659USD181

Current assets

Assets classified as current under the normal operating cycle or one-year boundary. Not all current assets can be converted immediately into cash.

PeriodValueUnitDays
At 2014-06-30141,208,016USD
At 2013-12-3138,249,485USD

Interest expense

Borrowing costs recognized as interest expense. This is distinct from cash interest paid and may not include every capitalized borrowing cost.

PeriodValueUnitDays
2014-04-01 to 2014-06-302,032USD91
2014-01-01 to 2014-06-307,073USD181
2013-04-01 to 2013-06-30231,756USD91
2013-01-01 to 2013-06-30473,072USD181

Current liabilities

Obligations classified as current under the operating-cycle or one-year boundary. The balance includes more than short-term borrowing.

PeriodValueUnitDays
At 2014-06-302,739,254USD
At 2013-12-316,834,037USD

Current accounts payable

Current amounts owed to suppliers for goods and services received. This is one component of current liabilities, not all accrued obligations.

PeriodValueUnitDays
At 2014-06-30415,791USD
At 2013-12-313,395,067USD

Net current accounts receivable

Current customer receivables after the allowance for credit loss. The balance is not cash collected or a guarantee of collection.

PeriodValueUnitDays
At 2014-06-30219,238USD
At 2013-12-31336,318USD

Research and development expense

Research and development costs recognized as expense. Capitalization policies and acquired projects can make this differ from total cash invested in development.

PeriodValueUnitDays
2014-04-01 to 2014-06-302,709,702USD91
2014-01-01 to 2014-06-305,539,001USD181
2013-04-01 to 2013-06-307,787,901USD91
2013-01-01 to 2013-06-3012,740,161USD181

Common shares outstanding

Common shares outstanding at the reporting date. This point-in-time count differs from the weighted-average shares used for earnings per share and can exclude other share classes.

PeriodValueUnitDays
At 2014-06-3029,344,020shares
At 2013-12-3122,159,446shares

Additional paid-in capital

Capital contributed above par value under this concept. It records historical contributions, not the current value of the equity or cash on hand.

PeriodValueUnitDays
At 2014-06-30205,289,691USD
At 2013-12-3189,177,556USD

Accumulated other comprehensive income or loss

Cumulative other comprehensive items after tax, such as translation and unrealized hedging or securities effects. These amounts have not passed through net income.

PeriodValueUnitDays
At 2014-06-30-47,749USD

Gross property, plant and equipment

Cost of property, plant and equipment before accumulated depreciation. Historical cost does not indicate current value or replacement cost.

PeriodValueUnitDays
At 2014-06-303,303,869USD
At 2013-12-313,300,275USD

Accumulated depreciation on property, plant and equipment

Cumulative depreciation, depletion and amortization recorded against property, plant and equipment. It measures cost allocation to date, not physical wear or market value.

PeriodValueUnitDays
At 2014-06-303,240,019USD
At 2013-12-313,232,003USD

Other noncurrent assets

Noncurrent assets the filer does not present separately. The composition differs by filer and is described only in the filing.

PeriodValueUnitDays
At 2014-06-3070,944USD
At 2013-12-31131,555USD

Prepaid expenses and other current assets

Prepayments and other current assets grouped under this concept. The balance is not cash and its composition differs by filer.

PeriodValueUnitDays
At 2014-06-30493,356USD
At 2013-12-31762,243USD

Comprehensive income or loss

Net income plus other comprehensive income after tax. It includes unrealized items that net income excludes and is not a cash measure.

PeriodValueUnitDays
2014-04-01 to 2014-06-30-4,581,288USD91
2014-01-01 to 2014-06-30-9,124,572USD181
2013-04-01 to 2013-06-30-8,277,391USD91
2013-01-01 to 2013-06-30-13,915,768USD181

General and administrative expense

General and administrative costs reported under this concept, separate from selling expense. Filers group overhead differently, so compare presentation before comparing companies.

PeriodValueUnitDays
2014-04-01 to 2014-06-302,121,120USD91
2014-01-01 to 2014-06-304,034,071USD181
2013-04-01 to 2013-06-30903,406USD91
2013-01-01 to 2013-06-301,950,014USD181

Depreciation expense

Depreciation recognized for the period under this concept. It is a noncash allocation of asset cost and may exclude amortization and depletion reported elsewhere.

PeriodValueUnitDays
2014-04-01 to 2014-06-306,430USD91
2014-01-01 to 2014-06-3012,747USD181
2013-01-01 to 2013-06-3011,092USD181

Proceeds from issuing common stock

Cash received from issuing common stock during the period. It is gross of costs only where the filer reports it so, and it does not include noncash issuances.

PeriodValueUnitDays
2014-01-01 to 2014-06-30116,191,285USD181

Change in accounts receivable

The cash flow adjustment for the change in receivables during the period. A positive value under this concept means receivables grew and reduced operating cash flow.

PeriodValueUnitDays
2014-01-01 to 2014-06-30-117,080USD181
2013-01-01 to 2013-06-30-24,504USD181

Change in accounts payable

The cash flow adjustment for the change in payables during the period. A positive value under this concept means payables grew and added to operating cash flow.

PeriodValueUnitDays
2014-01-01 to 2014-06-30-2,979,276USD181
2013-01-01 to 2013-06-302,737,604USD181

Inspect the source

Entity
Intra-Cellular Therapies, Inc. / CIK 0001567514
Captured
2026-09-21T17:20:04.465Z
SEC response SHA-256
d515a2828c30b442b80d2f88dbecd3b8d47803a78a686cc6f7c16f5ab9f2019e

Current SEC company facts · Download the original response snapshot (gzip) · Download the selected JSON

Every published concept a filing tagged, with the periods it covered, as reported in that filing at capture time. Forms 10-K, 10-K/A, 10-Q, 10-Q/A, 20-F, 20-F/A, 40-F, 40-F/A. A filing page needs at least 8 published concepts. Later filings can restate these values; the company history pages show the latest-filed value per period.

Public company accounting reference, not market prices, returns, an investment recommendation, or ALPHAC performance. Validate a separately constructed return series with the validation API; accounting values are not returns.

Use this in research

A financial period ends before its results become public. Use the filing date as a minimum availability boundary, inspect amendments, and retain the original filing vintage when testing historical signals. This latest-filed selection can contain information unavailable at the time.

These pages do not supply prices, total-return histories, corporate-action adjustments or a tradable universe. Build those inputs separately before evaluating a strategy. A profitable backtest can still reflect selection bias or costs that were left out.

Research methodology · Execution and cost assumptions · Check backtest overfitting

Build with the open-source tools

Use these accounting records as inspectable inputs. When you have constructed a return series, the validation tools can help test its statistical evidence and preserve the result with its limitations.

Read the published dataset with Python
import json
from urllib.request import urlopen

with urlopen("https://canlicapital.com/company-data/0001567514.json") as response:
    record = json.load(response)
print(record["fetched_at"])
print(record["policy"])
for concept in record["concepts"]:
    print(concept["tag"], next(iter(concept["observations"])))